Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rollover Study; Multicentre, Phase III, Open-label Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed Study PVO-1A-301 or PVO-1A-202/PVO-1A-204 and May Benefit From Palovarotene Therapy.

NCT05027802 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT05027802
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05027802 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rollover Study; Multicentre, Phase III, Open-label Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed Study PVO-1A-301 or PVO-1A-202/PVO-1A-204 and May Benefit From Palovarotene Therapy.
Lead sponsor
Ipsen
Phase
Phase 3
Overall status
Completed
Start date
March 14, 2022
Completion date
November 30, 2024
Enrollment
61 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

fibrodysplasia ossificans progressiva (fop)